Home / Latest Reports / Leishmaniasis Treatment Market

Leishmaniasis Treatment Market by Type and Application- Global Industry Analysis & Forecast to 2027

Published On : January 2021 Pages : 157 Category: Pharma & Healthcare Report Code : HC0114840

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

Leishmaniasis Treatment Market by Type(Pentamidine,Meglumine Antimoniate,Amphotericin B,Hydroxyl Amidine Stilbene)Application (Cutaneous Leishmaniasis,Visceral Leishmaniasis)- Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

Leishmaniasis Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.The disease caused by the Leishmania parasites is leishmaniasis. The Leishmania parasite is a single protozoan cell that is transmitted by the bite of a parasite-infected female phlebotomine sand fly. There are over 20 recorded species of Leishmania that are transmitted by the bite of infected female phlebotomine sandflies to humans.

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • SouthAmerica
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • iCo Therapeutics
  • Merck
  • Dafra Pharma
  • AEterna Zentaris
  • Eurofins Advinus
  • AEterna Zentaris AG
  • Pieris Pharmaceuticals
  • AEterna Zentaris AG

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2021 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Leishmaniasis Treatment Market, ByType, Estimates and Forecast, 2017-2027 ($Million)

o    Pentamidine, Meglumine Antimoniate

o    Amphotericin B

o    Hydroxyl Amidine Stilbene

·         Leishmaniasis Treatment Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)

o    Cutaneous Leishmaniasis

o    Visceral Leishmaniasis

·         Leishmaniasis Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)

o    iCo Therapeutics

o    Merck

o    Dafra Pharma

o    AEterna Zentaris

o    Eurofins Advinus

o    AEterna Zentaris AG

o    Pieris Pharmaceuticals

o    AEterna Zentaris AG

·         Leishmaniasis Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Leishmaniasis Treatment Market, By Country

o    U.S. Leishmaniasis Treatment Market

o    Canada Leishmaniasis Treatment Market

o    Mexico Leishmaniasis Treatment Market

o    Europe

§  Europe Leishmaniasis Treatment Market, By Country

·         Germany Leishmaniasis Treatment Market

o    UK Leishmaniasis Treatment Market

o    France Leishmaniasis Treatment Market

o    RussiaLeishmaniasis Treatment Market

o    Italy Leishmaniasis Treatment Market

o    Rest of Europe Leishmaniasis Treatment Market

o    Asia-Pacific

§  Asia-Pacific Leishmaniasis Treatment Market, By Country

o    ChinaLeishmaniasis Treatment Market

o    Japan Leishmaniasis Treatment Market

o    South KoreaLeishmaniasis Treatment Market

o    India Leishmaniasis Treatment Market

o    Southeast AsiaLeishmaniasis Treatment Market

o    Rest of Asia-Pacific Leishmaniasis Treatment Market

o    South America

§  South AmericaLeishmaniasis Treatment Market

o    Brazil Leishmaniasis Treatment Market

o    ArgentinaLeishmaniasis Treatment Market

o    ColumbiaLeishmaniasis Treatment Market

o    Rest of South America Leishmaniasis Treatment Market

o    Middle East and Africa

§  Middle East and AfricaLeishmaniasis Treatment Market

o    Saudi ArabiaLeishmaniasis Treatment Market

o    UAELeishmaniasis Treatment Market

o    EgyptLeishmaniasis Treatment Market

o    NigeriaLeishmaniasis Treatment Market

o    South Africa Leishmaniasis Treatment Market

o    Rest of MEA Leishmaniasis Treatment Market

 

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Leishmaniasis Treatment Market, By Type

5.1.     Introduction

5.2.     Global Leishmaniasis Treatment Revenue and Market Share by Type  (2017-2021)

5.2.1.  Global Leishmaniasis Treatment Revenue and Revenue Share by Type  (2017-2021)

5.3.     Pentamidine

5.3.1.  Global Pentamidine Revenue and Growth Rate (2017-2021)

5.4.     MeglumineAntimoniate

5.4.1.  Global MeglumineAntimoniate Revenue and Growth Rate (2017-2021)

5.5.     Amphotericin B

5.5.1.  Global Amphotericin B Revenue and Growth Rate (2017-2021)

5.6.     Hydroxyl AmidineStilbene

5.6.1.  Global Hydroxyl AmidineStilbene Revenue and Growth Rate (2017-2021)

6.       Leishmaniasis Treatment Market, By Application

6.1.     Introduction

6.2.     Global Leishmaniasis Treatment Revenue and Market Share by Application (2017-2021)

6.2.1.  Global Leishmaniasis Treatment Revenue and Revenue Share by Application (2017-2021)

6.3.     Cutaneous Leishmaniasis

6.3.1.  Global Cutaneous Leishmaniasis Revenue and Growth Rate (2017-2021)

6.4.     Visceral Leishmaniasis

6.4.1.  Global Visceral Leishmaniasis Revenue and Growth Rate (2017-2021)

7.       Leishmaniasis Treatment Market, By Region

7.1.     Introduction

7.2.     Global Leishmaniasis Treatment Revenue and Market Share by Regions

7.2.1.  Global Leishmaniasis Treatment Revenue by Regions (2017-2021)

7.3.     North America Leishmaniasis Treatment by Countries

7.3.1.  North America Leishmaniasis Treatment Revenue and Growth Rate (2017-2021)

7.3.2.  North America Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2021)

7.3.3.  United States

7.3.3.1.  United StatesLeishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.3.4.  Canada

7.3.4.1.  Canada Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.3.5.  Mexico

7.3.5.1.  Mexico Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.     Europe Leishmaniasis Treatment by Countries

7.4.1.  Europe Leishmaniasis Treatment Revenue and Growth Rate (2017-2021)

7.4.2.  Europe Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2021)

7.4.3.  Germany

7.4.3.1.  Germany Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.4.  France

7.4.4.1.  France Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.5.  UK

7.4.5.1.  UK Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.6.  Russia

7.4.6.1.  Russia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.7.  Italy

7.4.7.1.  Italy Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.     Asia-Pacific Leishmaniasis Treatment by Countries

7.5.1.  Asia-Pacific Leishmaniasis Treatment Revenue and Growth Rate (2017-2021)

7.5.2.  Asia-Pacific Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2021)

7.5.3.  China

7.5.3.1.  China Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.4.  Japan

7.5.4.1.  Japan Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.5.  Korea

7.5.5.1.  Korea Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.6.  India

7.5.6.1.  India Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.     South America Leishmaniasis Treatment by Countries

7.6.1.  South America Leishmaniasis Treatment Revenue and Growth Rate (2017-2021)

7.6.2.  South America Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2021)

7.6.3.  Brazil

7.6.3.1.  Brazil Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.4.  Argentina

7.6.4.1.  Argentina Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.5.  Columbia

7.6.5.1.  Columbia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.     Middle East and Africa Leishmaniasis Treatment by Countries

7.7.1.  Middle East and Africa Leishmaniasis Treatment Revenue and Growth Rate (2017-2021)

7.7.2.  Middle East and Africa Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2021)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.5.  Egypt

7.7.5.1.  Egypt Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.7.  South Africa

7.7.7.1.  South Africa Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.8.  Turkey

7.7.8.1.  Turkey Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)

8.       Company Profiles

8.1.     iCo Therapeutics

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     Merck

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     DafraPharma

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     AEternaZentaris

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     EurofinsAdvinus

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     AEternaZentaris AG

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Pieris Pharmaceuticals

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     AEternaZentaris AG

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

9.       Leishmaniasis Treatment Market Forecast (2022-2027)

9.1.     Global Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2022-2027)

9.2.     Leishmaniasis Treatment Market Forecast by Regions (2022-2027)

9.2.1.  North America Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.1.1.  United States Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.1.2.  Canada Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.1.3.  Mexico Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.  Europe Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.1.  Germany Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.2.  France Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.3.  UK Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.4.  Russia Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.5.  Italy Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.2.6.  Rest of Europe Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.  Asia-Pacific Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.1.  China Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.2.  Japan Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.3.  Korea Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.4.  India Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.5.  Southeast Asia Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.3.6.  Rest of Asia-Pacific Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.4.  South America Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.4.1.  Brazil Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.4.2.  Argentina Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.4.3.  Columbia Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.4.4.  Rest of South America Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.  Middle East and Africa Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.1.  Saudi Arabia Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.2.  United Arab Emirates Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.3.  Egypt Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.4.  Nigeria Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.5.  South Africa Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.6.  Turkey Leishmaniasis Treatment Market Forecast (2022-2027)

9.2.5.7.  Rest of Middle East and Africa Leishmaniasis Treatment Market Forecast (2022-2027)

9.3.     Leishmaniasis Treatment Market Forecast by Type  (2022-2027)

9.3.1.  Leishmaniasis Treatment Forecast by Type  (2022-2027)

9.3.2.  Leishmaniasis Treatment Market Share Forecast by Type  (2022-2027)

9.4.     Leishmaniasis Treatment Market Forecast by Application (2022-2027)

9.4.1.  Leishmaniasis Treatment Forecast by Application (2022-2027)

9.4.2.  Leishmaniasis Treatment Market Share Forecast by Application (2022-2027)

 

List of Tables

List of Tables and Figures:

Figure United States Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Leishmaniasis Treatment Revenue and Revenue Share by Type (2017-2019)
Figure Global Pentamidine Revenue and Growth Rate (2017-2019)
Figure Global MeglumineAntimoniate Revenue and Growth Rate (2017-2019)
Figure Global Amphotericin B Revenue and Growth Rate (2017-2019)
Figure Global Hydroxyl AmidineStilbene Revenue and Growth Rate (2017-2019)
Table Global Leishmaniasis Treatment Revenue and Revenue Share by Application (2017-2019)
Figure Global Cutaneous Leishmaniasis Revenue and Growth Rate (2017-2019)
Figure Global Visceral Leishmaniasis Revenue and Growth Rate (2017-2019)
Table Global Leishmaniasis Treatment Revenue by Regions (2017-2019)
Figure North America Leishmaniasis Treatment Growth Rate (2017-2019)
Figure North America Leishmaniasis Treatment Revenue and Growth Rate (2017-2019)
Figure North America Leishmaniasis Treatment by Countries (2017-2019)
Figure North America Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Leishmaniasis Treatment Growth Rate (2017-2019)
Figure United States Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Canada Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Mexico Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Europe Leishmaniasis Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Leishmaniasis Treatment by Countries (2017-2019)
Figure Europe Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Germany Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Leishmaniasis Treatment Growth Rate (2017-2019)
Figure France Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Leishmaniasis Treatment Growth Rate (2017-2019)
Figure UK Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Russia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Italy Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Rest of Europe Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Leishmaniasis Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Leishmaniasis Treatment by Countries (2017-2019)
Figure Asia-Pacific Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Leishmaniasis Treatment Growth Rate (2017-2019)
Figure China Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Japan Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Korea Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Leishmaniasis Treatment Growth Rate (2017-2019)
Figure India Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Southeast Asia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Leishmaniasis Treatment Growth Rate (2017-2019)
Figure South America Leishmaniasis Treatment Revenue and Growth Rate (2017-2019)
Figure South America Leishmaniasis Treatment by Countries (2017-2019)
Figure South America Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Brazil Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Argentina Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Columbia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Rest of South America Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Leishmaniasis Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Leishmaniasis Treatment by Countries (2017-2019)
Figure Middle East and Africa Leishmaniasis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Leishmaniasis Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Egypt Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Nigeria Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Leishmaniasis Treatment Growth Rate (2017-2019)
Figure South Africa Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Turkey Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Leishmaniasis Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table iCo Therapeutics Leishmaniasis Treatment Financial Overview
Table Merck Leishmaniasis Treatment Financial Overview
Table DafraPharmaLeishmaniasis Treatment Financial Overview
Table AEternaZentarisLeishmaniasis Treatment Financial Overview
Table EurofinsAdvinusLeishmaniasis Treatment Financial Overview
Table AEternaZentaris AG Leishmaniasis Treatment Financial Overview
Table Pieris Pharmaceuticals Leishmaniasis Treatment Financial Overview
Table AEternaZentaris AG Leishmaniasis Treatment Financial Overview
Figure Global Leishmaniasis Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Leishmaniasis Treatment Market Forecast by Regions (2019-2027)
Figure North America Leishmaniasis Treatment Market Forecast (2019-2027)
Figure United States Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Canada Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Mexico Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Europe Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Germany Leishmaniasis Treatment Market Forecast (2019-2027)
Figure France Leishmaniasis Treatment Market Forecast (2019-2027)
Figure UK Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Russia Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Italy Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Rest of Europe Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Leishmaniasis Treatment Market Forecast (2019-2027)
Figure China Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Japan Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Korea Leishmaniasis Treatment Market Forecast (2019-2027)
Figure India Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Southeast Asia Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Leishmaniasis Treatment Market Forecast (2019-2027)
Figure South America Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Brazil Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Argentina Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Columbia Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Rest of South America Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Leishmaniasis Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Egypt Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Nigeria Leishmaniasis Treatment Market Forecast (2019-2027)
Figure South Africa Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Turkey Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Leishmaniasis Treatment Market Forecast (2019-2027)
Figure Global Leishmaniasis Treatment Forecast by Type (2019-2027)
Figure Global Leishmaniasis Treatment Market Share Forecast by Type (2019-2027)
Figure Global Leishmaniasis Treatment Forecast by Type (2019-2027)
Figure Global Leishmaniasis Treatment Forecast by Application (2019-2027)
Figure Global Leishmaniasis Treatment Market Share Forecast by Application (2019-2027)
Figure Global Leishmaniasis Treatment Forecast by Application (2019-2027)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

Request Sample Enquire Before Buying Request for Customization

Request Sample